Keymed Biosciences Inc. (2162.HK) HKSE

74.00

+3.7(+5.26%)

Updated at September 29 04:08PM

Currency In HKD

Keymed Biosciences Inc.

Address

Building D2

Chengdu, 610219

China

Phone

86 28 8861 0620

Sector

Healthcare

Industry

Biotechnology

Employees

1258

First IPO Date

July 08, 2021

Key Executives

NameTitlePayYear Born
Dr. Bo ChenExecutive Chairman & Chief Executive Officer5.4M1975
Dr. Gang XuSenior Vice President & Executive Director1.88M1975
Dr. Changyun WangSenior Vice President & Executive Director3.21M1966
Mr. Yanrong ZhangChief Financial Officer, Vice President & Joint Company Secretary01987
Dr. Qian JiaSenior Vice President01965
Ms. Pak Yu Tam A.C.I.S., A.C.S.Joint Company Secretary0N/A

Description

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.